Immunisation Recommendations For Adults In Australia (Page 2 of 3) in pdf

Key:

ABLV = Australian bat lyssavirus

HPV = Human papillomavirus vaccine

13vPCV = 13-valent pneumococcal conjugate vaccine

dT = Diphtheria-tetanus vaccine

HZ = Herpes zoster vaccine

23vPPV = 23-valent pneumococcal polysaccharide vaccine

dTpa = Diphtheria-tetanus-acellular pertussis vaccine (reduced

JE = Japanese encephalitis vaccine

QIV = Quadrivalent seasonal influenza vaccine

antigen formulation)

HepA = Hepatitis A vaccine

MenBV = Meningococcal serogroup B vaccine

TIV = Trivalent seasonal influenza vaccine

HepB = Hepatitis B vaccine

4vMenCV = Quadrivalent meningococcal conjugate vaccine

VV = Varicella vaccine

Hib = Haemophilus influenzae type b vaccine

MMR = Measles-mumps-rubella vaccine

a The National Immunisation Program Schedule is updated periodically and is available on the Immunise Australia website ( ). The current version of the 10th

edition Australian Immunisation Handbook is available online ( /internet/immunise/publishing.nsf/Content/Handbook10-home).

b Influenza vaccine is recommended annually for any adult who wishes to reduce the likelihood of becoming ill with influenza. Only certain QIVs are funded under the NIP for adults with a

medical condition that predisposes them to severe influenza; women who will be pregnant during the influenza season; non-Indigenous adults ≥65 years of age; and all Aboriginal and Torres

Strait Islander adults. Vaccination is recommended (but not funded) for women planning for pregnancy and for adults in specific occupations. When both QIV and TIV formulations are suitable,

QIV is preferred; however, TIV is an acceptable alternative. For further details, refer to the current version of the 10th edition Handbook online.

c A single dose of 23vPPV is recommended and funded for all non-Indigenous persons at 65 years of age. A single catch-up dose is funded for those aged >65 years who did not receive a dose

at age 65. A dose of 23vPPV is recommended and funded for Aboriginal and Torres Strait Islander adults at 50 years of age, followed by a 2nd dose 5 years later. The 23vPPV is also

recommended for younger adults with specified conditions which increase their risk of invasive pneumococcal disease (IPD) (funded on the NIP for Aboriginal and Torres Strait Islander adults

only). Those with highest risk of IPD also require a dose of 13vPCV; the 13vPCV dose should precede the 1st dose of 23vPPV by 2 months. Refer to the current version of the 10th edition

Handbook online for details regarding recommendations for these patients, including the use of repeat doses of 23vPPV.

d For adults born during or after 1966, 2 doses of MMR are recommended, unless the individual is documented to be immune.

e For healthcare workers, people working in early childhood education and care, staff of long-term care facilities and staff of correctional facilities, if they are non-immune or have only received

1 dose of MMR.

For women planning pregnancy or as soon as possible after delivery, if seronegative for rubella.

g For adults who are non-immune to varicella (serology test recommended to test for previous natural infection, but not previous vaccination), particularly non-immune healthcare workers, adults

who work in early childhood education and care and in long-term care facilities, women before pregnancy or postpartum, and contacts of people with impaired immunity. Two doses of varicella

vaccine are required to achieve adequate protection.

h Vaccine registered for ≥50 years. From November 2016, a single dose will be funded on the NIP for adults at 70 years of age (with a short-term catch-up program for adults aged 71–79) as

routine vaccination of this age group is expected to obtain the greatest benefits against herpes zoster and its complications.

For adults ≥50 years of age who have not received a booster dose of a tetanus-containing vaccine in the previous 10 years.

Adults who have received a tetanus-prone wound should receive a dT booster dose if more than 5 years have elapsed since their last dose.

k Any adult who requires a dose of dT vaccine should be encouraged to do so with dTpa which provides additional protection against pertussis.

For any adult who wishes to reduce the likelihood of becoming ill with pertussis and who has not previously been vaccinated with dTpa. Due to the increased morbidity associated with

pertussis in the elderly, adults aged ≥65 years should be offered a single dTpa booster if they have not received one in the previous 10 years.

m For healthcare workers and those working in early childhood education and care, a booster dose of dTpa is recommended if 10 years have elapsed since a previous dose.

n dTpa vaccine is recommended as a single dose during the third trimester of each pregnancy (optimally between 28 and 32 weeks), including closely spaced pregnancies. For any pregnancy

where antenatal vaccination does not occur, vaccination as soon as possible after the delivery of the infant (preferably before hospital discharge) will provide some indirect protection to the

infant. Any adult household contact or carers of infants aged <6 months should receive a single dose of dTpa if 10 years have elapsed since a previous dose.

o For adults who are at increased risk of acquiring hepatitis A due to their occupation, lifestyle or medical status. For those who require both the hepatitis A and hepatitis B vaccines, the

combined hepatitis A/hepatitis B vaccine can be considered.

p For non-immune adults who are at increased risk of acquiring hepatitis B due to their occupation, lifestyle or medical status (including household and sexual contacts of persons with chronic

hepatitis B infection) and Indigenous adults. For those who require both the hepatitis A and hepatitis B vaccines, the combined hepatitis A/hepatitis B vaccine can be considered.

Immunisation Recommendations For Adults In Australia Page 2

Related Articles

Related forms

Related Categories